From University of Texas Health Science Center, San Antonio (MAS); Cincinnati Eye Institute, Cincinnati (DMM); Carolina Retina Center, Columbia, SC (JGG); Wake Forest Baptist Medical Center, Winston Salem, NC (CMG); Alimera Sciences, Alpharetta, GA (BK); University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom (CB); Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom (FG); and UC Irvine Health Gavin Herbert Eye Institute, Irvine, CA (BDK).
© 2018 Singer, Miller, Gross, etc.; licensee SLACK Incorporated. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International ( https://creativecommons.org/licenses/by/4.0). This license allows users to copy and distribute, to remix, transform, and build upon the article, for any purpose, even commercially, provided the author is attributed and is not represented as endorsing the use made of the work.
This study was presented at the American Academy of Ophthalmology Annual Meeting, New Orleans, November 11–14, 2017.
Financial support for this study was provided by Alimera Sciences (Alpharetta, GA). The sponsor participated in data collection, data management, data analysis, interpretation of the data, preparation of the manuscript, and review of the manuscript. Employees of Alimera Sciences participated in conducting the study, data acquisition analysis, and reporting.
Dr. Singer has received financial support from Aerpio, Allergan, Ampio, Genentech, and Regeneron. Dr. Miller has received financial support from Alcon, Genentech, and Regeneron; has been a consultant for Alimera and Bausch + Lomb; and has a personal financial interest in Vortex. Dr. Gross has received financial support from Acucela, Ohr, and Regeneron. Dr. Greven is involved in clinical trials with Genentech (Roche) and Allergan. Mr. Kapik is an employee of Alimera Sciences. Dr. Bailey is a consultant for Allergan, Alcon, Bayer, Alimera Sciences, Roche and Novartis. Dr. Ghanchi has been a consultant for Alimera, Allergan, Bayer, and Novartis and has received grants and funding from Allergan, Bayer, Novartis, pSivida, Oraya, and Sakura.Dr. Kuppermann is involved in clinical research with Alcon, Alimera, Allegro, Allergan, Apellis, Genentech, GSK, J-Cyte, Neurotech, Ophthotech, Regeneron, and ThromboGenics, and has been a consultant for Aerpio, Alcon, Alimera, Allegro, Allergan, Ampio, Dose, Genentech, Glaukos, Novartis, Ophthotech, Regeneron, and SciFluor.
The authors thank Shuo Yang, PhD, of Quorum Consulting for statistical support. Medical writing assistance was provided by Emma Mycroft at Helios Medical Communications, supported by Alimera Sciences.
Address correspondence to Michael A. Singer, MD, 9157 Huebner Rd., San Antonio, TX 78240; email: